Urology News and Research

Latest Urology News and Research

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Endo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks.

3 Sep 2009

Uroplasty highlights the result of OrBIT trial of its Urgent PC System

Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results published in the September, 2009 edition of THE JOURNAL OF UROLOGY(R) from the OrBIT trial of its Urgent PC System.

3 Sep 2009

New findings on molecular imaging and prostate cancer

A new study published in the September issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET)/computer tomography (CT) scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed.

2 Sep 2009

Retail clinics offer better quality care at lower costs than other venues

A new study by Rand Corporation, published in the Annals of Internal Medicine, concludes retail clinics provide quality care at lower costs and equal or better quality than other urgent care options.

1 Sep 2009

FDA approves Watson Pharmaceuticals' ANDA for Levonorgestrel tablets

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Levonorgestrel Tablets, 0.75 mg for over-the-counter use in women ages 17 and above, as well as for prescription use in women under the age of 17.

29 Aug 2009

TomoTherapy to discuss the uses of CT scanner-based device at the 10th Biennial ESTRO Conference

TomoTherapy Incorporated announced today that there will be more than 40 presentations at the 10th Biennial ESTRO Conference on Physics and Radiation Technology for Clinical Radiotherapy that explore use of the TomoTherapy treatment system. The TomoTherapy system -- a versatile, CT scanner-based device that integrates image guidance for increased treatment accuracy and helical radiation therapy delivery for enhanced tumor targeting -- is helping cancer centers advance patient care around the world.

28 Aug 2009

Resonant Medical's multi-anatomy Clarity System to be exhibited at ESTRO, Netherlands

Resonant Medical, an innovator in soft tissue planning, image-guidance and adaptive radiotherapy products, today announced that the Company will be exhibiting the next generation of its multi-anatomy Clarity System at the 10th Biennial Meeting of The European Society of Therapeutic Radiology and Oncologists (ESTRO), being held in Maastricht, Netherlands.

27 Aug 2009

Haber’s Electromolecular Propulsion technology offers high molecular separation speeds

Haber, Inc. (“Haber”), (OTC: HABE), a Delaware corporation headquartered in Arlington, Mass., with proprietary technologies in the separations sciences and environmentally friendly processing of gold bearing ores, announced today that it has formed a wholly owned subsidiary incorporated in Delaware called “EMP Diagnostics Inc.” (“EDI”). The business of the new company will focus on the application of Haber’s Electromolecular Propulsion technology (EMP). EMP is a separation technology that achieves unrivaled molecular separation speeds and has other unique capabilities not attainable with electrophoresis or liquid chromatography.

27 Aug 2009

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

26 Aug 2009

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer.

24 Aug 2009

P&G's global pharmaceuticals business sold to Warner Chilcott for $3.1 billion

The Procter & Gamble Company and Warner Chilcott plc today announced an agreement for the sale of P&G's global pharmaceuticals business to Warner Chilcott for an up-front cash payment of $3.1 billion.

24 Aug 2009

Study reveals that increased neurostimulation market offers growth for device industries

The device industry would do well to focus on the treatment needs of individuals suffering from nerve-related disorders as implanted technologies that deliver electrical stimulation begin to supplant drugs for treating certain nerve-related disorders.

24 Aug 2009

FDA issues complete response letter regarding the NDA for carisbamate

The U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for carisbamate, an anti-epileptic drug in development, announced Ortho-McNeil-Janssen Pharmaceuticals, Inc.

23 Aug 2009

Results of PCF funded study could impact the standard of care for prostate cancer patients

Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).

21 Aug 2009

New findings to prevent urinary tract infections

Researchers at Duke University Medical Center may have a new way to stop and even prevent the urinary tract infections (UTIs) that plague more than a third of all adults, some of them repeatedly.

21 Aug 2009

Physician shortage limits even insured patients' access to care

CBS News reports that just having insurance coverage "doesn't guarantee access" to health care, because there is s shortage of primary care doctors to provide treatment. "Baystate Medical Center is the second busiest emergency room in Massachusetts. They treat over 100,000 patients a year, but here's the thing: according to Dr. Niels Rathlev, who runs the ER, a quarter of them don't need his services." Rathlev says it would be "more appropriate" for those people to see a primary care doctor. "'The majority of patients who are frequent utilizers of the emergency department actually have insurance,' Rathlev said. 'They have a primary care physician, but they choose to come to the ER because they don't have access.'"

20 Aug 2009

Health Informatics Consulting to oversee practice management & EHR implementation at New Jersey ambulatory centers

Two new ambulatory surgical centers under construction in Northern New Jersey will streamline and improve the quality of care for patients through a partnership with Health Informatics Consulting (http://www.hi-consulting.net), a leader in healthcare technology.

20 Aug 2009

Intracacies of doctors' fees difficult to unravel

"For the most part, doctor fees are a mystery. If people see a doctor who is part of their insurance network, they are responsible only for deductibles and co-payments, and the price the health insurer pays is often a secret," The New York Times reports. "And if people see a doctor outside their network, they usually have no idea what the charge will be - even though they are responsible for most of it - until the bill comes."

19 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Watson Pharmaceuticals offers unsecured notes up to $850 million

Watson Pharmaceuticals, Inc. (NYSE: WPI), a specialty pharmaceutical company, today announced that it is offering up to $850 million aggregate principal amount of five and ten year senior unsecured notes in a registered public offering.

19 Aug 2009

Urology News and Research

Latest Urology News and Research

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Uroplasty highlights the result of OrBIT trial of its Urgent PC System

New findings on molecular imaging and prostate cancer

Retail clinics offer better quality care at lower costs than other venues

FDA approves Watson Pharmaceuticals' ANDA for Levonorgestrel tablets

TomoTherapy to discuss the uses of CT scanner-based device at the 10th Biennial ESTRO Conference

Resonant Medical's multi-anatomy Clarity System to be exhibited at ESTRO, Netherlands

Haber’s Electromolecular Propulsion technology offers high molecular separation speeds

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

P&G's global pharmaceuticals business sold to Warner Chilcott for $3.1 billion

Study reveals that increased neurostimulation market offers growth for device industries

FDA issues complete response letter regarding the NDA for carisbamate

Results of PCF funded study could impact the standard of care for prostate cancer patients

New findings to prevent urinary tract infections

Physician shortage limits even insured patients' access to care

Health Informatics Consulting to oversee practice management & EHR implementation at New Jersey ambulatory centers

Intracacies of doctors' fees difficult to unravel

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Watson Pharmaceuticals offers unsecured notes up to $850 million

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Urology News and Research

Latest Urology News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in